Transactions under Novozymes’ stock buyback program

May 20, 2019 09:23 ET | Source: Novozymes A/S Novozymes A/S

Please read the full announcement in the attached PDF

Attachment

2019_13_Stock_Buybackprogram_EN

Attachments

2019_13_Stock_Buybackprogram_EN

2019_13_Stock_Buybackprogram_EN...

Recommended Reading

November 05, 2026 02:10 ET | Source: Novonesis (Novozymes A/S)

9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook

COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026...
Read More
November 05, 2026 01:58 ET | Source: Novonesis (Novozymes A/S)

Interim report 9M 2026

Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38%...
Read More